CROI (Conference on Retroviruses and Opportunistic Infections)

The Latest

TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects

A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.

By Martha Kempner

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows

Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.

By Sony Salzman

What You Need to Know About the Second Person Likely Cured of HIV

Richard Jefferys, an expert in HIV cure research, spoke to TheBodyPro about this new case of HIV remission -- and the danger in rushing to publish these stories, especially for people who live with stigma.

By Kenyon Farrow

UK Patient Likely to Be the Second Person Cured of HIV: Two Further Cases at CROI 2019 of HIV Remission After Allogenic Stem Cell Transplants

The procedure used in this case was similar to that used in the only previously confirmed HIV cure case, "Berlin patient" Timothy Ray Brown, albeit with a somewhat less aggressive approach.

By Simon Collins for HIV i-Base

CROI 2019: What News to Expect in HIV Science and Policy

TheBodyPro is covering all the latest in HIV science at the biggest annual gathering of HIV researchers in the U.S. Here's a preview of what's to come.

By Sony Salzman

Reducing Risk of Myocardial Infarction in HIV-Positive People

This year at CROI 2018 a few studies tried to explore possible mechanisms for the association of increased myocardial infarction risk and abacavir use.

By Satyajit Das for HIV i-Base

M184V Mutation Associated With Increased Risk of Viral Blip but Not Viral Failure With 3TC-Based Dual Therapy

A retrospective analysis presented at CROI 2018 looked at risk of viral rebound in people who switched to lamivudine (Epivir, 3TC)-based dual antiretroviral therapy.

By Satyajit Das for HIV i-Base

Efavirenz Might Decrease Effectiveness of the Vaginal Contraceptive Ring

Efavirenz (Sustiva, Stocrin) alters hormone exposure from the vaginal ring in HIV positive women, similar or greater to that previously reported with oral hormonal contraceptives.

By Polly Clayden for HIV i-Base

Retaining Patients in PrEP Care Faces Many Hurdles, Studies Show

Most people who could benefit from pre-exposure prophylaxis are not accessing it, the U.S. Centers for Disease Control and Prevention revealed at this year's Conference on Retroviruses and Opportunistic Infections.

By Barbara Jungwirth

CROI 2018: Research for the Front Lines

Rob Newells, executive director of the AIDS Project of the East Bay, gives his personal (U.S.-centered, black MSM-focused) highlights from CROI 2018.

By Rob Newells for AVAC: Global Advocacy for HIV Prevention